American judge rejects Bayer's request to block Johnson & Johnson's prostate cancer drug claims.

A federal judge in the United States has rejected Bayer's request to ban Johnson & Johnson from releasing false advertisements worth billions of dollars claiming that their drug can reduce the risk of prostate cancer death by half. In a ruling late Friday, U.S. District Judge Dale Ho in Manhattan said Bayer had not shown it was likely to succeed, with its lawsuit claiming Johnson & Johnson's promotion of its drug Erleada caused irreparable harm and could undermine confidence in Bayer's own drug Nubeqa. Both Bayer and Johnson & Johnson did not immediately respond to requests for comment after hours.